What Treatment Protocols And Clinical Results Can Clinics Expect When Operating Blue Light Phototherapy Devices For Inflammatory Acne And Keloid Scars? Key Insights For Clinical Success

Clinics can generally structure blue light phototherapy as twice-weekly treatments for six consecutive weeks. For inflammatory acne, this course is expected to reduce papules and pustules by suppressing Cutibacterium acnes and local inflammation. For keloid scars, the same six-week schedule may reduce inflammation around the lesion and improve its visual appearance, although scar response is less predictable and should not be treated as equivalent to established keloid therapies.

The practical expectation is improvement, not guaranteed clearance. Blue light is most useful as a non-invasive, well-tolerated adjunct for inflammatory acne and selected inflamed scars, with outcomes determined by wavelength, irradiance, treatment consistency, diagnosis, and patient skin response.

What the Treatment Protocol Usually Looks Like

Standard acne schedule

The core protocol described for moderate-to-severe papular-pustular acne is two sessions per week for six weeks, for a total of approximately 12 treatments.

Individual session duration depends on the device’s output, treatment area, and operating instructions. Clinics should use the manufacturer’s validated exposure settings rather than transferring energy parameters from another blue light or IPL system.

Wavelength and delivery

Blue light devices commonly operate within approximately 410–490 nm, with systems near 415–420 nm frequently used for acne-oriented applications.

The treatment may be delivered through high-intensity LEDs or a blue-light IPL configuration. These systems should not be treated as interchangeable because irradiance, pulse characteristics, cooling, and tissue exposure can differ substantially.

Patient preparation

The treatment area should be clean and free of makeup, sunscreen, and products that may interfere with light delivery. The clinic should document the patient’s baseline lesion count, inflammation, scar characteristics, skin type, medications, and history of photosensitivity.

Eye protection is required whenever the device’s instructions call for it. Photosensitizing medications and products must be reviewed before treatment.

Expected Results for Inflammatory Acne

Reduction in inflammatory lesions

Blue light primarily targets the inflammatory component of acne. It activates porphyrins associated with C. acnes, producing reactive oxygen species that damage the bacteria while generally avoiding tissue ablation.

Clinics can therefore expect the clearest benefit in red, inflamed papules and pustules, rather than in comedones, deep scarring, or long-standing textural defects.

Timing of improvement

Some patients notice reduced redness or fewer new inflammatory lesions during the treatment course. More meaningful assessment should occur after the full six-week protocol and, ideally, at a follow-up several weeks later.

Results are usually gradual and variable. Blue light does not permanently eliminate acne susceptibility, so maintenance treatment or conventional acne management may be needed.

Role of combined wavelengths

A combined blue-and-red-light approach may provide broader acne coverage. Blue light acts more superficially against acne-associated bacteria, while red light penetrates more deeply and may help moderate inflammatory signaling and support tissue recovery.

If a clinic uses both wavelengths, it should follow a protocol validated for that specific device. The results of a dual-wavelength system should not be assumed from blue-light-only data.

What blue light does not reliably correct

Blue light is not a primary treatment for atrophic acne scars, deep comedonal disease, severe nodulocystic acne, or established pigmentation. Those problems may require medications, chemical procedures, lasers, microneedling, or other specialist interventions.

Expected Results for Keloid Scars

Proposed clinical objective

For post-traumatic keloids, the six-week twice-weekly protocol is intended to reduce perilesional inflammation and improve the scar’s overall appearance.

Potential visible changes may include less surrounding redness, reduced inflammatory activity, and a more settled appearance. The reference protocol does not establish a predictable degree of flattening, volume reduction, or permanent remission.

Set realistic expectations

Keloids are biologically active scars with a significant recurrence risk. Blue light should therefore be presented as a potential adjunctive option, not a replacement for established treatments such as intralesional corticosteroids, other injectable therapies, silicone-based management, pressure therapy, or specialist surgical planning.

Clinics should photograph and measure the scar before treatment. Useful follow-up measures include height, width, redness, tenderness, itch, firmness, and patient-reported symptoms.

Evidence is less mature than for acne

The rationale for treating keloids includes reducing local inflammation and potentially influencing abnormal fibroblast activity. However, the clinical evidence and predictability of blue light for keloid remodeling are less established than its antibacterial rationale in inflammatory acne.

Practitioners should avoid promising scar removal. The more defensible claim is possible improvement in inflammation and appearance after a structured course, with response varying by scar age, size, location, and recurrence tendency.

How Clinics Should Control Treatment Delivery

Calibrate irradiance and exposure

Clinical effect depends on the delivered dose, not simply the nominal wavelength. Important controls include irradiance, exposure time, pulse duration, treatment distance, and treatment-area coverage.

Excessive delivery can cause erythema, edema, blistering, or temporary acneiform worsening. The correct setting is the one supported by the device protocol and tolerated by the patient—not necessarily the highest available output.

Distinguish LED from IPL systems

A blue LED panel and a 420 nm IPL system can both be described as blue-light treatments, but their energy delivery and tissue interaction may differ.

Clinics should maintain separate operating protocols, consent language, training requirements, and maintenance schedules for each platform.

Protect the skin barrier

Blue light is generally non-ablative and non-thermal when appropriately administered. Nevertheless, patients may experience temporary warmth, redness, dryness, or sensitivity, particularly when treatment is combined with irritating acne products.

A conservative skincare plan and clear instructions about sun protection help reduce avoidable irritation. Patients should be told not to increase exposure or add photosensitizing products between sessions.

Understanding the Trade-offs

Benefits and limitations

The main operational advantages are that treatment is non-invasive, generally well tolerated, and associated with little or no downtime when correctly dosed.

The limitations are equally important: results are not permanent, effects are stronger for inflammatory than non-inflammatory acne, and keloid outcomes are difficult to predict.

Treatment intensity versus tolerance

Increasing irradiance or exposure may appear attractive when early improvement is limited. However, aggressive delivery can produce inflammation that worsens patient comfort and may undermine adherence.

A controlled, repeatable course is more clinically useful than a high-intensity approach that causes avoidable adverse effects.

Avoid unsupported outcome claims

The supplied references include a potential acne reduction of up to approximately 60% in some blue-light contexts. That figure should not be presented as a guaranteed clinic outcome because results vary by device, wavelength, study design, disease severity, and whether blue light was combined with red light or another modality.

For keloids, clinics should report observed changes rather than promise a fixed percentage reduction or complete flattening.

Do not confuse blue light with photorejuvenation IPL

Broader IPL photorejuvenation protocols commonly involve three to six sessions at three- to four-week intervals, targeting pigmentation, vascularity, and photodamage.

That schedule should not be automatically applied to blue-light acne or keloid treatment. The indication, wavelength, energy profile, and biological target are different.

How Clinics Should Measure Clinical Success

Acne assessment

Record baseline and follow-up inflammatory and non-inflammatory lesion counts. Also document redness, new lesion formation, patient-reported oiliness, irritation, and adherence to the treatment schedule.

A meaningful result is usually a sustained reduction in inflammatory activity, not simply temporary redness immediately after a session.

Keloid assessment

Use standardized photographs with consistent lighting, distance, and positioning. Track scar height, firmness, redness, symptoms, and changes in the tissue surrounding the lesion.

Follow-up after the six-week course is important because a scar may appear less inflamed before any longer-term change in texture or prominence becomes clear.

Safety assessment

At every visit, check for excessive erythema, edema, blistering, pain, pigmentary change, photosensitivity, and acne flares. Treatment should be paused and medically reviewed when the reaction exceeds the device’s expected tolerance profile.

How to Apply This to Your Clinic

A sound protocol should be based on the specific device’s validated settings, the patient’s diagnosis, and objective before-and-after measurements.

If your primary focus is inflammatory acne: Use a structured twice-weekly course for six weeks, with blue light directed primarily at papular and pustular disease and reassessment after the full course.
If your primary focus is keloid scars: Present six weeks of twice-weekly treatment as an adjunctive trial aimed at reducing inflammation and improving appearance, not as a guaranteed scar-removal protocol.
If your primary focus is patient comfort and throughput: Use a non-ablative, consistently dosed system with clear eye protection, screening, and post-treatment instructions.
If your primary focus is measurable outcomes: Record lesion counts or scar dimensions, standardize photography, and review results at the end of treatment and during follow-up.
If your primary focus is safety: Control irradiance, exposure time, pulse duration, wavelength selection, and photosensitizer use rather than increasing output empirically.

When clinics combine realistic indications, validated settings, and objective follow-up, blue light phototherapy becomes a practical tool for managing inflammatory skin activity without overstating what it can achieve.

Summary Table:

Condition	Protocol	Expected Results	Limitations
Inflammatory Acne	Twice weekly for 6 weeks; 410–490 nm; LED or IPL	Reduced papules/pustules; gradual improvement; may need maintenance	Not for comedones, scarring, or nodulocystic acne; variable results
Keloid Scars	Twice weekly for 6 weeks; adjunctive trial	Reduced perilesional inflammation; improved appearance	Unpredictable; not a replacement for established therapies; limited evidence

Looking to integrate blue light phototherapy into your clinic? BELIS offers professional-grade devices with validated protocols for acne and scar management. Our portfolio includes advanced laser and light systems designed for clinics and premium salons. Contact us today to learn how our solutions can enhance your treatment offerings and patient satisfaction. Get in touch with our experts.